Blood cancer cell removal system and method based on thermal activation and filtration of anti-tumor drug

Abstract

The invention discloses a blood cancer cell removal system and method based on thermal activation and filtration of an anti-tumor drug, and the system comprises a heating activation assembly, a mixing cavity, a drug removal unit and a mechanical filtration unit, the mixing cavity is connected with a broad-spectrum anti-tumor drug solution connecting pipe and a blood connecting pipe; the heating activation assembly comprises a water bath tank and a water bath inner cavity arranged in the water bath tank, the mixing cavity is communicated with the water bath inner cavity through a pipeline, the medicine removing unit comprises a three-stage countercurrent washing system in which normal saline circulates, a liquid inlet of the three-stage countercurrent washing system is communicated with the water bath inner cavity, and a liquid outlet of the three-stage countercurrent washing system is communicated with the water bath inner cavity. According to the technical scheme, the dual effects of thermal activation killing of broad-spectrum anti-tumor drugs and multi-stage mechanical filtering are combined, efficient removal of cancer cells is achieved, the mechanical filtering module removes residual cancer cells and fragments subsequently, the mechanical filtering module is used for filtering the residual cancer cells, and therefore the cancer cells can be efficiently removed. The medication and blood transfusion safety of a patient is ensured.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of medical blood cancer cell removal, in particular to a blood cancer cell removal system and method based on anti-tumor drug heat activation and filtration. BACKGROUND

[0002] In clinical surgical treatment, intraoperative autologous blood transfusion technology has become an important blood support method in many surgical scenarios because it can effectively reduce the infection risk and immune rejection risk caused by allogeneic blood transfusion. However, when the surgical subject is a tumor patient, this technology has a key technical problem: if there are residual cancer cells in the transfused blood, these cancer cells may re-enter the patient's body, thereby causing tumor metastasis, which seriously affects the postoperative rehabilitation effect and quality of life of the patient, greatly limiting the application of intraoperative autologous blood transfusion technology in tumor surgery.

[0003] To solve the problem of removing residual cancer cells in blood, the existing technology mainly adopts two types of processing methods: The first is a physical filtration method, represented by a white blood cell filter. This type of filter device intercepts cancer cells in blood through filter mesh aperture, but due to the filtering principle and existing filter mesh manufacturing process, its removal effect on cancer cells with a diameter of less than 10 μm is not good, and the removal rate can only reach 70%-85%, which cannot achieve efficient removal of cancer cells; at the same time, physical filtration can only mechanically intercept cancer cells, and cannot destroy the biological activity of unintercepted cancer cells. The intercepted cancer cells may re-enter the blood due to filter device failure, etc., and still have the ability to cause tumor metastasis.

[0004] The second is a chemical treatment method, which usually uses broad-spectrum anti-tumor drugs (such as cisplatin) to directly contact blood to kill cancer cells. However, this method has significant defects: on the one hand, if broad-spectrum anti-tumor drugs are used to act on cancer cells through systemic administration, they will have strong toxicity to normal tissues and organs of the patient, causing a series of adverse reactions and increasing the patient's treatment burden; on the other hand, if the concentration of chemotherapy drugs is increased to directly contact blood in order to improve the killing effect of cancer cells, it will cause red blood cell hemolysis to intensify, with a hemolysis rate usually exceeding 5%, which seriously damages the normal function of red blood cells in blood and cannot guarantee the safety of transfused blood.

[0005] In summary, in the existing technology, neither the single physical filtration method nor the single chemical treatment method can simultaneously meet the two main requirements of clinical intraoperative autologous blood transfusion: efficient removal of cancer cells and safe transfusion of red blood cells. There is a technical contradiction between the two, and a technical solution for intraoperative autologous blood cancer cell removal is needed to break through this contradiction and promote the safe application of intraoperative autologous blood transfusion technology in tumor surgery. SUMMARY

[0006] The application provides a blood cancer cell removal system and method based on heat activation and filtration of antitumor drugs, and can solve the problem of the technical contradiction between single physical filtration and single chemical treatment.

[0007] To achieve the above object, in a first aspect, the application provides the following technical scheme: a blood cancer cell removal system based on heat activation and filtration of antitumor drugs, comprising a heating activation assembly, a mixing cavity, a drug removal unit and a mechanical filtration unit, the mixing cavity is connected with a broad-spectrum antitumor drug solution connecting pipe and a blood connecting pipe, the heating activation assembly comprises a water bath tank and a water bath inner cavity arranged in the water bath tank, the mixing cavity is connected with the water bath inner cavity through a pipeline, the drug removal unit comprises a three-stage countercurrent washing system with physiological saline flowing therein, the three-stage countercurrent washing system is connected with the water bath inner cavity through a liquid inlet, and the three-stage countercurrent washing system is connected with the mechanical filtration unit through a liquid outlet, the technical scheme of the application combines the double effects of heat activation killing of broad-spectrum antitumor drugs and multi-stage mechanical filtration, realizes efficient removal of cancer cells, the subsequent mechanical filtration module removes residual cancer cells and fragments, the three-stage countercurrent washing system of the drug removal module can reduce the residual amount of broad-spectrum antitumor drugs in blood to below the nephrotoxicity threshold of the broad-spectrum antitumor drugs, avoids the risk of toxic side effects of traditional chemotherapy drugs when the drugs are administered systemically or in high concentration, and guarantees the safety of drug administration and blood transfusion of patients.

[0008] Preferably, the water bath tank is connected with a circulating water pipe, and a heating element and a circulating liquid pump are installed on the circulating water pipe, so that the water temperature in the water bath tank can be kept in a relatively accurate range.

[0009] Preferably, the heating element is electrically connected with a temperature control timing module, so that the working time of the heating element can be accurately controlled.

[0010] As preferred, the tertiary countercurrent washing system comprises three washing tanks, the inside of the washing tank is provided with a filler layer, the upper part of the filler layer is provided with a distributor, the liquid inlet of the tertiary countercurrent washing system is connected with the distributor of the first washing tank, transition liquid pipes are connected between adjacent washing tanks, one end of the transition liquid pipe is connected with the distributor, and the other end is connected with the bottom of the washing tank, the first washing tank is connected with a physiological saline outlet pipe, the last washing tank is connected with a physiological saline inlet pipe and the liquid outlet of the tertiary countercurrent washing system, the filler layers of adjacent washing tanks are connected through a physiological saline transition pipe, the mixed solution is uniformly sprayed to the surface of the filler layer along the distributor, flows downward along the filler surface under the action of gravity, forms a liquid film, another physiological saline flows upward from the bottom of the filler layer, fully contacts with the liquid film on the surface of the filler layer, forms a phase interface, because the concentration of the broad-spectrum antitumor drug in the mixed solution is much higher than the concentration of impurities in the physiological saline, the broad-spectrum antitumor drug will diffuse from the liquid film on the mixed solution side to the liquid film on the physiological saline side through the phase interface, the flow directions of the mixed solution and the physiological saline are opposite, and the broad-spectrum antitumor drug in the mixed solution can be fully removed through the three washing tanks.

[0011] As preferred, a driving liquid pump is arranged on the transition liquid pipe, so that the continuous transfer of the mixed solution between the washing tanks can be ensured.

[0012] As preferred, the mechanical filtration unit comprises a filter membrane and at least one polyester filter screen, the polyester filter screen can intercept large particle fragments, and the filter membrane can capture cancer cells and fragments.

[0013] In the second aspect, the application further provides a method for removing blood cancer cells based on the heat activation and filtration of antitumor drugs according to the first aspect, which comprises the following steps: S1, mixing a broad-spectrum antitumor drug solution with blood in a mixing chamber; S2, passing the mixed solution into a water bath inner cavity to be incubated in the constant-temperature water in the water bath tank, so as to induce DNA cross-linking damage of cancer cells and kill the cancer cells; S3, passing the mixed solution into a drug removal unit to flow through three washing tanks in sequence, while physiological saline flows through the washing tanks in reverse, so as to flush the broad-spectrum antitumor drug solution in the mixed solution; S4, passing the blood from which the broad-spectrum antitumor drug solution is removed into a mechanical filtration unit to capture large particle fragments and cancer cells.

[0014] Further, the temperature of the constant-temperature circulating water in the water bath tank in step S2 is 42℃, and the water bath time is 15-20 minutes.

[0015] Further, the ratio between the physiological saline and the mixed solution flowing through the drug removal unit is 3:1.

[0016] Compared with the prior art, the present application has the following advantages: The technical scheme of the present application combines the dual effects of heat-activated killing of broad-spectrum antitumor drugs and multi-stage mechanical filtration, realizes efficient removal of cancer cells, and the subsequent mechanical filtration module removes residual cancer cells and fragments. The drug removal module uses a three-stage countercurrent washing system, which can reduce the residual amount of broad-spectrum antitumor drugs in the blood to below the nephrotoxicity threshold of broad-spectrum antitumor drugs, avoiding the risk of toxic side effects of traditional chemotherapy drugs when administered systemically or in high concentrations in contact with blood, and ensuring patient safety when taking medication and blood transfusion. The present application can completely remove cancer cells from the blood before intraoperative autologous blood transfusion, thereby solving the risk of tumor metastasis caused by residual cancer cells in the blood during autologous blood transfusion, and providing a safety guarantee for autologous blood transfusion in cancer patients; In the prior art, single physical filtration cannot meet the requirement of >98% cancer cell removal rate, and single chemical treatment has the defects of high hemolysis rate and high toxic side effects, and both cannot balance efficient removal and blood safety. The present application achieves simultaneous satisfaction of >98% cancer cell removal rate and <1% red blood cell hemolysis rate and non-toxicity of residual broad-spectrum antitumor drugs through multi-module collaborative design, breaking through the core bottleneck of the prior art; The system and method are suitable for blood purification before surgical bleeding and autologous blood transfusion in most cancer patients such as liver cancer and ovarian cancer, do not need complex adjustment for different cancer types, are suitable for various clinical scenarios, solve the problem of limited applicability of traditional technology in autologous blood transfusion during cancer surgery, and have high clinical popularization value BRIEF DESCRIPTION OF DRAWINGS Figure 1 is a system structure diagram according to the present application.

[0017] Reference signs: 1, heating activation assembly, 11, water bath tank, 12, water bath inner cavity, 2, broad-spectrum antitumor drug solution connecting pipe, 3, blood connecting pipe, 4, mixing cavity, 5, circulating water pipe, 6, circulating liquid pump, 7, heating element, 8, temperature control timing module, 9, drug removal unit, 91, washing tank, 92, distributor, 93, physiological saline outlet pipe, 94, filler layer, 95, transition liquid pipe, 96, driving liquid pump, 97, physiological saline transition pipe, 99, physiological saline inlet pipe, 10, mechanical filtration unit, 101, polyester filter screen, 102, filter membrane. DETAILED DESCRIPTION

[0018] The technical solutions in the embodiments of the present application will be described clearly and completely below with reference to the drawings in the embodiments of the present application.

[0019] The present application can solve the technical contradiction between the existing single physical filtration method and single chemical treatment. Figure 1The technical scheme is shown as follows: a blood cancer cell removal system based on heat activation and filtration of an anti-tumor drug, comprising a heating activation assembly 1, a mixing cavity 4, a drug removal unit 9 and a mechanical filtration unit 10, the mixing cavity 4 is connected with a broad-spectrum anti-tumor drug solution connecting pipe 2 and a blood connecting pipe 3, the heating activation assembly 1 comprises a water bath tank 11 and a water bath inner cavity 12 arranged in the water bath tank 11, the mixing cavity 4 is connected with the water bath inner cavity 12 through a pipeline, the drug removal unit 9 comprises a three-stage countercurrent washing system with physiological saline flowing through the inside, the three-stage countercurrent washing system is connected with the water bath inner cavity 12 through a liquid inlet, and the three-stage countercurrent washing system is connected with the mechanical filtration unit 10 through a liquid outlet. The technical scheme of the present application combines the double effects of heat activation killing of the broad-spectrum anti-tumor drug and multi-stage mechanical filtration, realizes efficient removal of cancer cells, the subsequent mechanical filtration module removes residual cancer cells and fragments, the drug removal module adopts the three-stage countercurrent washing system, the residual amount of the broad-spectrum anti-tumor drug in the blood can be reduced to less than the nephrotoxicity threshold of the broad-spectrum anti-tumor drug, the risk of toxic side effects of traditional chemotherapy drugs when the drugs are administered systemically or contacted with blood at a high concentration is avoided, and the safety of drug administration and blood transfusion of patients is ensured.

[0020] Specifically, the mixing cavity 4 is connected with the broad-spectrum anti-tumor drug solution (such as cisplatin) and the blood pipeline at the same time, which can ensure that the two fluids are stably mixed at a predetermined ratio, such as blood:broad-spectrum anti-tumor drug solution=10:1, to avoid red blood cell hemolysis caused by too high local concentration of the broad-spectrum anti-tumor drug or affect the cancer killing effect caused by too low concentration; the water bath tank 11 and the built-in water bath inner cavity 12 form a double-layer structure, which can make the mixed solution in a uniform and constant temperature environment throughout the process, ensure sufficient heat activation of the broad-spectrum anti-tumor drug, and then realize that the DNA cross-linking damage rate of cancer cells is greater than 99%, and avoid red blood cell destruction caused by local overheating. The three-stage countercurrent washing system of the drug removal unit 9 is designed by maximizing the concentration gradient of the forward flow of the mixed solution and the reverse flow of the physiological saline, the removal rate of the broad-spectrum anti-tumor drug is increased by more than 30%, the residual amount of the broad-spectrum anti-tumor drug in the blood can be reduced to less than 0.01 μg / mL, which is much lower than the nephrotoxicity threshold 0.05 μg / mL of the broad-spectrum anti-tumor drug. At the same time, the combined design of the mechanical filtration unit 10 can cover the full-size interception of large particle fragments and micro cancer cells, avoid the problem that a single filtration element cannot completely remove small diameter cancer cells, and finally the total removal rate of cancer cells is greater than 98.5%.

[0021] Specifically, the mixing cavity 4 is made of medical polytetrafluoroethylene material, has a volume of 50 mL, and is internally provided with a polytetrafluoroethylene stirrer with a stirring speed of 50 rpm; the broad-spectrum anti-tumor drug solution connecting pipe and the blood connecting pipe are both medical silica gel pipes with an inner diameter of 3 mm and a length of 30 cm, which are adapted to the interface of a clinical infusion device and can control the flow rate through an infusion pump; the water bath tank 11 is made of 304 stainless steel and has a volume of 2 L.

[0022] In the embodiment, the water bath tank 11 is circumscribed by a circulating water pipe 5, the circulating water pipe 5 is provided with a heating element 7 and a circulating liquid pump 6, which can ensure that the water temperature in the water bath tank 11 is in a relatively accurate range. Specifically, the circulating liquid pump 6 drives the constant temperature water to continuously flow in the circulating water pipe 5, which can avoid the local temperature difference in the water bath tank and make the water temperature fluctuation in the tank ≤±0.5℃, thereby ensuring the temperature consistency of the mixed solution in the water bath cavity. The heating element and the circulating liquid pump are linked, which can raise the water temperature from room temperature to 42℃ within 5 minutes, and the temperature rising process is stable without temperature overshoot, thereby avoiding the damage of red blood cells caused by short-term high temperature. Meanwhile, the heating element 7 is electrically connected with a temperature control timing module 8, which can accurately control the working time of the heating element 7. The temperature sensor is used to collect the water temperature in the water bath tank 11 in real time, which is fed back to the temperature control module, and then the power of the heating element is adjusted. For example, when the water temperature is lower than 41.9℃, the heating element works at full power; when the water temperature is higher than 42.1℃, the heating element is powered off, so that the water temperature control accuracy is ±0.1℃, thereby ensuring the stable activation efficiency of the broad-spectrum antitumor drug. The timing function is linked with the inflow action of the mixed solution, which can accurately record the holding time of the mixed solution in the water bath cavity, thereby avoiding the incomplete killing of cancer cells caused by insufficient holding time or the increase of the hemolysis rate of red blood cells caused by too long holding time. The temperature control timing module 8 takes an STM32F103 single-chip microcomputer as the core, a PT100 platinum resistance sensor, and a probe inserted into the water bath tank is connected with the temperature control module through a shielded wire, thereby avoiding electromagnetic interference.

[0023] In the embodiment, as the specific structure of the three-stage countercurrent washing system, the three-stage countercurrent washing system comprises three washing tanks 91, the inside of the washing tank 91 is provided with a filler layer 94, the upper part of the filler layer 94 is provided with a distributor 92, the liquid inlet of the three-stage countercurrent washing system is connected with the distributor 92 of the first washing tank 91, the transition liquid pipes 95 are connected between the adjacent washing tanks 91, one end of the transition liquid pipe 95 is connected with the distributor 92, and the other end is connected with the bottom of the washing tank 91, the physiological saline outlet pipe 93 is connected with the first washing tank 91, the physiological saline inlet pipe 99 is connected with the last washing tank 91, and the liquid outlet of the three-stage countercurrent washing system, the filler layers 94 of the adjacent washing tanks 91 are connected through the physiological saline transition pipes 97, the mixed solution is uniformly sprayed to the surface of the filler layer 94 along the distributor 92, flows downward along the filler surface under the action of gravity, forms a liquid film, another physiological saline flows upward from the bottom of the filler layer 94, fully contacts with the liquid film on the surface of the filler layer 94, forms a phase interface, because the concentration of the broad-spectrum antitumor drug in the mixed solution is much higher than the concentration of the impurities in the physiological saline, the broad-spectrum antitumor drug will diffuse from the liquid film on the mixed solution side to the liquid film on the physiological saline side through the phase interface, the flow directions of the mixed solution and the physiological saline are opposite, and the broad-spectrum antitumor drug in the mixed solution can be fully removed through the three washing tanks 91. Specifically, the multi-hole spraying design of the distributor 92 can uniformly spray the mixed solution to the surface of the filler layer, avoid that the local liquid flow is concentrated to cause that part of the solution flows out without fully contacting with the physiological saline, and make the uniformity of the distribution of the solution on the filler layer > 90%. The filler layer 94 provides a large specific surface area, can make the mixed solution form a thin liquid film, fully contact with the physiological saline flowing in the opposite direction, and the broad-spectrum antitumor drug molecules can quickly diffuse from the mixed solution side to the physiological saline side. Specifically, 3 medical polypropylene washing tanks 91, the top of each washing tank 91 is provided with a feeding port connected with the distributor 92, the bottom is provided with a discharging port connected with the transition liquid pipe 95, and the middle of the side wall is provided with a physiological saline interface connected with the physiological saline transition pipe 97; the distributor 92 in each washing tank is a multi-hole spraying head, 36 spraying holes are uniformly distributed on the spraying head, the spraying head is located 5 cm above the filler layer 94, and the solution can cover the entire cross section of the filler layer. The filler layer 94 is a medical ceramic ring, the height of the filler layer in each washing tank is 8 cm, and a multi-hole support plate is arranged at the bottom of the filler layer to prevent the filler from being lost and not hinder the flow of the solution.

[0024] Wherein, the transition liquid pipe 95 is provided with a driving liquid pump 96, which can ensure the continuous transfer of the mixed solution between the washing tanks 91, accurately control the conveying flow rate of the mixed solution through the driving liquid pump 96, avoid the flow rate fluctuation caused by the liquid level difference change of the washing tank, ensure the consistent residence time of each stage of washing, and ensure the stable removal efficiency of the broad-spectrum antitumor drug.

[0025] In the embodiment, the mechanical filtration unit 10 comprises a filter membrane 102 and at least one polyester filter screen 101, the polyester filter screen 101 can intercept large-particle debris, and the filter membrane 102 can capture cancer cells and debris, wherein the polyester filter screen 101 first intercepts large-particle impurities in the blood, such as cell debris with a diameter of >20 μm, blood clots, and unsolved broad-spectrum antitumor drug crystals, so as to avoid the micropores of the subsequent filter membrane from being blocked by such impurities, prolong the service life of the filter membrane 102, and the micropore size of the filter membrane 102 can accurately intercept residual cancer cells with a diameter of 5-10 μm, while not adsorbing normal blood cells. In the embodiment, two polyester filter screens 101 are arranged, the shell of the mechanical filtration unit 10 is made of medical ABS material, the first polyester filter screen, the second polyester filter screen, and the filter membrane 102 are sequentially arranged inside the shell from the inlet to the outlet, the filtration elements are sealed by silica gel sealing rings, so as to avoid solution short circuiting, and luer lock connectors are arranged at both ends of the shell, so as to be quickly connected with the liquid outlet pipe of the drug removal unit, and the filtration elements are convenient to disassemble and replace.

[0026] In the embodiment, a method based on the blood cancer cell removal system according to the above anti-tumor drug thermal activation and filtration is also provided, and the method comprises the following steps: S1, start the infusion pump of the blood connection pipe, the flow rate is 20 mL / min, and the in-surgery collected blood of a liver cancer patient, such as 300 mL, with a hemoglobin concentration of 120 g / L, is introduced into the mixing cavity; at the same time, the infusion pump of the broad-spectrum antitumor drug solution connection pipe is started, and 0.1 mg / mL of the broad-spectrum antitumor drug solution is introduced into the mixing cavity, wherein the broad-spectrum antitumor drug solution is 30 mL, the purity of the broad-spectrum antitumor drug is ≥99.5%, and the solvent is 0.9% physiological saline; the stirring rod is turned on, and after stirring for 5 minutes, the concentration of the broad-spectrum antitumor drug in the mixed solution is detected to be 0.0091 mg / mL, the concentration variation coefficient is 3.2%, and there is no hemolysis phenomenon; S2, the mixed solution is transported to the water bath inner cavity 12 through the infusion pump between the mixing cavity 4 and the water bath inner cavity 12; the temperature control timing module is set to a temperature of 42℃, and the incubation time is 18 minutes; during the incubation process, the temperature of the mixed solution is detected every 3 minutes, and is stable at 42℃±0.1℃; after 18 minutes, the cancer cell activity is detected by the MTT method, the death rate of liver cancer cells is 98.2%, and the red blood cell hemolysis rate is 0.6%; S3, the driving liquid pump is started, and the mixed solution after thermal activation is introduced into the first washing tank 91 at a flow rate of 200 mL / h; at the same time, the physiological saline infusion pump is started, and 0.9% physiological saline is introduced into the terminal washing tank at a flow rate of 600 mL / h; the mixed solution flows through the three washing tanks in sequence, and the physiological saline flows through the three washing tanks in reverse; the sample is taken from the outlet of the terminal washing tank, and the high-performance liquid chromatography method is used to detect that the residual amount of the broad-spectrum antitumor drug is 0.008 μg / mL; S4, the washed blood is passed into the mechanical filtration unit 10 at a flow rate of 150 mL / h; after filtration is completed, the filtrate is collected, and the number of cancer cells is detected using flow cytometry, and the results show that the cancer cell removal rate is 98.7%, the red blood cell recovery rate is 98.1%, and the white blood cell recovery rate is 95.3%.

[0027] In step S2, the temperature of the constant-temperature circulating water in the water bath tank 11 is 42℃, the water bath time is 15-20 minutes, the thermal activation temperature threshold of the broad-spectrum antitumor drug is 40℃, when the temperature is lower than 40℃, the cross-linking efficiency of the broad-spectrum antitumor drug with cancer cell DNA is <70%, and the cancer cell mortality rate is <80%; when the temperature is higher than 43℃, the fluidity of the red blood cell membrane is significantly increased, the cell membrane rupture rate is increased, and the hemolysis rate is >2%; when the temperature is 42℃, the cross-linking efficiency of the broad-spectrum antitumor drug is >95%, the cancer cell mortality rate is >98%, and the red blood cell hemolysis rate is <1%, which is the optimal temperature.

[0028] In addition, the ratio between the physiological saline flowing in the drug removal unit 9 and the mixed solution is 3:1.

[0029] After the effect of the above-mentioned embodiment is verified, through flow cytometry detection, the initial blood cancer cell concentration is 1x10 4 / mL, the reinfusion blood cancer cell concentration is 8 / mL, the removal rate = (1x10 4 -8) / 1x10 4 x100%=98.92%, which meets the clinical requirement of >98%. And through HPLC detection, the residual broad-spectrum antitumor drug in the reinfusion blood is 0.008 μg / mL, which is far lower than the nephrotoxicity threshold of the broad-spectrum antitumor drug, and there is no risk of kidney damage.

[0030] It should be noted that all directional indications (such as up, down, left, right, front, back, etc.) in the embodiments of the present application are only used to explain the relative positional relationship, movement condition, etc. between the components in a certain specific posture (as shown in the drawings), and if the specific posture changes, the directional indications will also change accordingly.

[0031] In addition, the description such as "first", "second" and the like in the present application is only for description purpose, and cannot be understood as indicating or implying the relative importance of the indicated technical features or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first", "second" can explicitly or implicitly include at least one of the features. In the description of the present application, the meaning of "a plurality of" is at least two, such as two, three, etc., unless otherwise specifically limited.

[0032] In the present application, unless otherwise explicitly specified and limited, the terms "connection", "fixation" and the like should be understood in a broad sense, for example, "fixation" can be fixed connection, or detachable connection, or integral; can be mechanical connection, or electrical connection; can be directly connected, or indirectly connected through intermediate medium, can be internal communication of two elements or interaction relationship of two elements, unless otherwise explicitly limited. For those skilled in the art, the specific meaning of the above terms in the present application can be understood according to the specific circumstances.

[0033] In addition, the technical solutions among various embodiments of the present application can be combined with each other, but it must be based on the fact that a person skilled in the art can realize it, when the combination of technical solutions appears contradictory or unachievable, it should be considered that the combination of technical solutions does not exist, nor is it within the protection scope required by the present application.

Claims

1. A blood cancer cell clearance system based on thermal activation and filtration of antitumor drugs, characterized in that, The device includes a heating activation component (1), a mixing chamber (4), a drug removal unit (9), and a mechanical filtration unit (10). The mixing chamber (4) is connected to a broad-spectrum antitumor drug solution connecting tube (2) and a blood connecting tube (3). The heating activation component (1) includes a water bath tank (11) and a water bath inner cavity (12) disposed inside the water bath tank (11). The mixing chamber (4) is connected to the water bath inner cavity (12) through a pipeline. The drug removal unit (9) includes a three-stage countercurrent washing system in which physiological saline flows. The inlet of the three-stage countercurrent washing system is connected to the water bath inner cavity (12), and the outlet of the three-stage countercurrent washing system is connected to the mechanical filtration unit (10).

2. The blood cancer cell clearance system based on thermal activation and filtration of antitumor drugs according to claim 1, characterized in that: The water bath tank (11) is connected to a circulating water pipe (5), and a heating element (7) and a circulating liquid pump (6) are installed on the circulating water pipe (5).

3. The blood cancer cell clearance system based on thermal activation and filtration of antitumor drugs according to claim 2, characterized in that: The heating element (7) is electrically connected to the temperature control timing module (8).

4. The blood cancer cell clearance system based on thermal activation and filtration of antitumor drugs according to claim 1, characterized in that: The three-stage countercurrent washing system includes three washing tanks (91). The washing tanks (91) are equipped with a packing layer (94) inside. A distributor (92) is provided above the packing layer (94). The inlet of the three-stage countercurrent washing system is connected to the distributor (92) of the first washing tank (91). A transition liquid pipe (95) is connected between adjacent washing tanks (91). One end of the transition liquid pipe (95) is connected to the distributor (92), and the other end is connected to the bottom of the washing tank (91). The first washing tank (91) is connected to a saline outlet pipe (93), and the last washing tank (91) is connected to a saline inlet pipe (99) and the outlet of the three-stage countercurrent washing system. The packing layers (94) of adjacent washing tanks (91) are connected by a saline transition pipe (97).

5. The blood cancer cell clearance system based on thermal activation and filtration of antitumor drugs according to claim 4, characterized in that: A drive pump (96) is provided on the transition liquid pipe (95).

6. The blood cancer cell clearance system based on thermal activation and filtration of antitumor drugs according to claim 1, characterized in that: The mechanical filtration unit (10) includes a filter membrane (102) and at least one polyester filter screen (101).

7. A method for a blood cancer cell clearance system based on thermal activation and filtration of antitumor drugs according to claim 1, characterized in that, Includes the following steps: S1. The broad-spectrum antitumor drug solution is mixed with blood in the mixing chamber (4); S2. The mixed solution is introduced into the inner cavity (12) of the water bath and kept warm in the constant temperature water of the water bath tank (11) to induce DNA cross-linking damage of cancer cells and kill cancer cells. S3. The mixed solution enters the drug removal unit (9) and flows sequentially through three washing tanks (91) in the forward direction. At the same time, physiological saline flows in the reverse direction through the washing tanks (91) to rinse the broad-spectrum antitumor drug solution in the mixed solution. S4. Blood after the broad-spectrum antitumor drug solution has been removed is passed into a mechanical filtration unit (10) to capture large particles and cancer cells.

8. The method for a blood cancer cell clearance system based on thermal activation and filtration of antitumor drugs according to claim 7, characterized in that: In step S2, the temperature of the constant temperature circulating water in the water bath tank (11) is 42℃, and the water bath time is 15-20 minutes.

9. The method for a blood cancer cell clearance system based on thermal activation and filtration of antitumor drugs according to claim 7, characterized in that: The ratio of physiological saline to mixed solution flowing in the drug clearance unit (9) is 3:1.

Images